MP Healthcare Venture Management (MPH), the corporate venturing unit of Mitsubishi Tanabe Pharma (MTP) and Mitsubishi Chemical, has invested as part of a consortium’s $12m backing for FerroKin BioSciences, a US-based biotechnology company developing treatments for iron overload in people’s blood.
Merchant bank Burrill & Company and venture capital firms Clarus Ventures and Healthcap Ventures also invested.